Photocure ASA: New data presented on Blue Light Cystoscopy with Cysview®/Hexvix® at the Société Internationale d'Urologie (SIU) 2016 Annual meeting
25 oct. 2016 09h28 HE
|
Photocure ASA
Oslo, Norway, October 25, 2016 Photocure ASA announced that new data on Blue Light Cystoscopy with Cysview®/Hexvix® were presented at the Société Internationale d'Urologie (SIU) Annual meeting,...
Photocure: Repeat use of Blue Light Cystoscopy with Hexvix®/Cysview® shows excellent tolerability
28 sept. 2016 09h08 HE
|
Photocure ASA
Oslo, Norway, September 28th, 2016: Photocure ASA announced today that a study published on-line in the peer reviewed Journal of Urology, shows that there is no significant statistical difference...
Photocure ASA: Share capital increase registered
13 sept. 2016 05h33 HE
|
Photocure ASA
Reference is made to the announcement on 6 September 2016 in respect of a capital increase of 35 000 new shares following exercise of employee share options in the company. The share capital...
Photocure ASA: Data published in World Journal of Urology show that Blue Light Cystoscopy with Hexvix® significantly improves detection of NMIBC
12 sept. 2016 02h00 HE
|
Photocure ASA
Oslo, Norway, September 12th, 2016: Photocure ASA announced today that data from the OPTIC III study: Optimized photodynamic diagnosis for transurethral resection of the bladder tumor (TURBT) in...
Photocure ASA: Update on management shareholdings and exercise of employee share options
06 sept. 2016 02h25 HE
|
Photocure ASA
Update on management shareholdings and exercise of employee share options in Photocure ASA ("the Company"). Oslo, Norway, 6 September 2016 1. Participants in the Photocure's share option...
Photocure Hosts Bladder Cancer Key Opinion Leader Breakfast in New York City
29 août 2016 04h00 HE
|
Photocure ASA
Oslo, Norway, August 29, 2016 -- Photocure ASA hosted on August 25 an educational event in New York aimed at institutional investors and analysts, which focused on the treatment of bladder cancer....
Photocure: Hexvix® marketing authorization approval in Australia
24 août 2016 03h52 HE
|
Photocure ASA
Oslo, Norway, August 24, 2016: Photocure ASA (OSE: PHO), announces that its partner and exclusive distributor, Juno Pharmaceuticals Pty Ltd, have received marketing authorization approval (MAA) for...
Photocure ASA: Results for second quarter and first half year 2016
23 août 2016 01h30 HE
|
Photocure ASA
Oslo, Norway, 23 August 2016: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, reported a sales revenue growth of 18 % to...
Photocure ASA: Presentation of the second quarter 2016 results and Hexvix/Cysview update
17 août 2016 04h55 HE
|
Photocure ASA
Photocure will present its second quarter report on Tuesday 23 August 2016 at Hotel Continental, Oslo, Norway. Additionally, Dr. Daneshmand will provide an update on Hexvix/Cysview following the...
Photocure ASA: CYSVIEW® GRANTED FDA APPROVAL OF NEW PREFILLED SYRINGE PRODUCT PACKAGING
11 août 2016 02h00 HE
|
Photocure ASA
New Cysview kit has an improved design providing healthcare professionals with an improved, simplified, and easy-to-use product. Oslo, Norway, August 11, 2016: Photocure ASA (OSE: PHO), announces...